Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cyclodextrin, particularly β-cyclodextrin and its derivatives, has been explored in preclinical (animal and cellular) studies as a potential agent to mitigate fatty liver disease (hepatic steatosis). Cyclodextrins are cyclic oligosaccharides known for their ability to encapsulate and solubilize lipophilic molecules, including cholesterol. In several animal studies, β-cyclodextrin has been shown to reduce hepatic triglyceride and cholesterol accumulation, likely by enhancing the removal of excess cholesterol from liver tissue and improving lipid metabolism. For example, research in mouse models of diet-induced non-alcoholic fatty liver disease (NAFLD) has demonstrated that cyclodextrin administration can decrease hepatic lipid content and attenuate inflammation associated with steatosis.

However, while these findings are promising, there is a lack of robust human clinical data supporting the safety and efficacy of cyclodextrin for the treatment of fatty liver disease. Most studies have been limited to laboratory and animal models, and the translation of these findings to human therapy is still unclear. Furthermore, high doses of cyclodextrin can be nephrotoxic and may cause other adverse effects, raising safety concerns for its use in humans. Therefore, while there is some scientific rationale and preclinical evidence supporting cyclodextrin as a potential therapy for fatty liver disease, high-quality clinical trials are needed before any recommendations can be made.

More about cyclodextrin
More about Fatty Liver Disease

Other ingredients used for Fatty Liver Disease

Other health conditions supported by cyclodextrin

Products containing cyclodextrin

Douglas Laboratories A.H.C.C. ® Plus